Top Stories
Immutep LAG-3 Failure Extinguishes Third Checkpoint Class Dreams, Extends Keytruda First-Line Lock
Immutep terminated its TACTI-004 Phase 3 trial of eftilagimod alpha (efti) plus pembrolizumab in first-line PD-L1 positive NSCLC after independent monitoring showed futility, according to Endpoints News. The LAG-3 agonist combined with Merck's Keytruda failed to demonstrate superiority over Keytruda alone in the 520-patient study. Pharmaphorum reported Immutep shares collapsed over 60% on the news, effectively ending industry hopes that LAG-3 could become a third major checkpoint inhibitor class alongside PD-1 and CTLA-4. Bristol Myers Squibb gained FDA approval for its LAG-3 antibody Opdualag in melanoma in 2022, but the class has failed to replicate the broad utility of PD-1 inhibitors. Immutep exits the first-line NSCLC market entirely, abandoning its lead program. Merck secures an extended runway for Keytruda monotherapy dominance in PD-L1 high NSCLC, with one fewer competitor threatening its $25B+ franchise. The failure particularly stings given LAG-3's biological rationale and early enthusiasm. What to watch: whether BMS pursues Opdualag combinations beyond melanoma or also scales back LAG-3 investment.
Salspera Files $91M IPO for Salmonella-Based Cancer Therapy Entering Phase 3
Salspera disclosed plans for a $91 million IPO to fund Phase 3 development of its salmonella-based oncolytic therapy for solid tumors, according to Fierce Biotech. The company engineers attenuated Salmonella typhimurium to selectively colonize and destroy tumor tissue while stimulating immune responses. Proceeds will support two Phase 3 registrational trials, though Fierce Biotech noted the company has not disclosed specific indications or trial designs in the filing. The approach represents one of the most unconventional mechanisms reaching late-stage development, competing in a crowded oncolytic space that includes oncolytic viruses from companies like Replimune and Candel Therapeutics. If successful, Salspera would establish the first approved bacteria-based cancer therapy, creating a new treatment modality. The IPO comes as biotech financing remains challenging, with most oncology IPOs in 2025-2026 significantly smaller than the 2020-2021 era. What to watch: trial design details and whether Salspera targets immunologically cold tumors where oncolytics theoretically offer the greatest benefit, or hot tumors where combination potential with checkpoint inhibitors exists.
Cancer Cell Protein Expulsion Mechanism Unveils New Immunotherapy Target Class
Researchers discovered that cancer cells can expel internal proteins onto their cell surface through a previously unknown mechanism, potentially creating a new class of immunotherapy targets for solid tumors, STAT News reported. The finding centers on the oncogene Src, which cancer cells essentially excrete onto their membranes where it becomes accessible to antibodies and CAR-T cells. According to STAT News, this addresses a longstanding challenge in solid tumor immunotherapy: most tumor-associated antigens are either intracellular (unreachable by antibodies) or shared with normal tissues (causing toxicity). The expelled proteins create tumor-specific surface targets without genetic engineering. Companies developing antibody or CAR-T platforms gain access to a potentially broad new target class that combines tumor specificity with surface accessibility. The mechanism appears distinct from traditional antigen presentation pathways, suggesting it may apply across multiple cancer types. What to watch: whether academic groups or biotechs can rapidly translate this into drug programs, and whether the Src target itself or the broader protein expulsion pathway offers more therapeutic leverage. Early movers in validating clinical relevance could establish significant IP positions.
Pipeline Watch
The American Society of Clinical Oncology released updated living guidelines emphasizing upfront biomarker testing before treatment initiation in driver mutation-negative Stage IV NSCLC, according to Targeted Oncology. The guidelines stress comprehensive molecular profiling to rule out actionable alterations before defaulting to immunotherapy-based regimens, reflecting the expanding roster of targetable drivers and the different risk-benefit profiles of IO versus targeted therapy. The update reinforces test-first strategies as standard of care even when PD-L1 status suggests IO eligibility.
A Phase 2a trial evaluating microbiome-modulating therapy in combination with allogeneic hematopoietic stem cell transplantation for blood cancers has completed patient enrollment, Targeted Oncology reported. The study tests whether engineered microbiome interventions can reduce graft-versus-host disease while preserving graft-versus-leukemia effects, a longstanding challenge in allo-HSCT. Results could inform development of microbiome therapeutics as standard adjuncts to transplant protocols, an area seeing increased investment from companies like Seres Therapeutics and Vedanta Biosciences.
The Regeneron Science Talent Search awarded more than $1.8 million to high school seniors, with multiple projects focused on computational approaches to blood cancer treatment and neural science applications in oncology, according to Regeneron. The top $250,000 award went to Connor Hill for work in computational mathematics. The competition highlights the pipeline of young researchers entering cancer biology and computational oncology, fields seeing rapid growth as AI and systems biology approaches proliferate across drug discovery.
Waiv emerged from AI oncology company Owkin with $33 million in funding to develop artificial intelligence tools for precision oncology treatment decisions, MedCity News reported. The spinout will focus on digital pathology and multi-modal data integration to guide therapy selection in complex cases. The financing underscores continued investor appetite for clinical decision support AI despite broader caution around healthcare AI hype, particularly when tied to established digital pathology platforms with validated datasets.
The FDA rolled out a unified adverse event monitoring platform consolidating seven separate dashboards into a single system, projecting $120 million in savings over five years, Fierce Pharma reported. While not oncology-specific, the system will affect safety monitoring for cancer drugs, potentially accelerating signal detection and regulatory response times. The modernization comes as the agency faces increasing scrutiny over post-market surveillance efficiency, particularly for accelerated approval products common in oncology.
Pfizer is shutting down Pfizer Ignite, its R&D services unit designed to support early-stage biotechs with discovery and development resources, according to Endpoints News. The closure reflects Pfizer's broader cost-cutting following its pandemic revenue peak and reduced appetite for distributed early-stage partnerships. For oncology startups, the move eliminates one avenue for non-dilutive preclinical support, though it may redirect Pfizer's oncology BD team toward more traditional acquisition and licensing deals.
Competitive Landscape
Immutep's Phase 3 failure extends a pattern of LAG-3 disappointments beyond BMS's narrow Opdualag melanoma approval, per Endpoints News and Pharmaphorum. The LAG-3 class has failed to achieve broad clinical utility despite initial enthusiasm, with no approvals in lung cancer where PD-1 inhibitors dominate. PD-1 inhibitors from Merck, BMS, and Roche maintain unchallenged supremacy in checkpoint inhibition, with no viable third class emerging after a decade of attempts. The dynamic suggests diminishing returns on me-too checkpoint programs and reinforces the difficulty of surpassing first-generation mechanisms.
| Checkpoint | Status | Broad Utility |
|---|---|---|
| PD-1/PD-L1 | Multiple Approvals | High |
| CTLA-4 | Combo Use | Moderate |
| LAG-3 | 1 Approval | Low |
Salspera's bacterial oncolytic approach joins a crowded field including viral oncolytics from Replimune and Candel, all competing for differentiation in immunologically cold tumors, according to Fierce Biotech. The space remains pre-commercial outside of Imlygic (T-VEC) in melanoma, with no clear platform leader. Whichever platform first demonstrates survival benefit in a large solid tumor indication will define the class and attract combination interest from checkpoint inhibitor makers. Current investors are essentially making mechanism bets without strong clinical proof-of-concept to guide platform selection.
The newly identified mechanism of cancer cells excreting internal proteins onto their surface inherently advantages large molecule modalities, STAT News reported. CAR-T developers like Gilead, BMS, and emerging players gain potential access to tumor-specific surface targets previously considered undruggable. Small molecule kinase inhibitor programs targeting intracellular oncoproteins may face new competition from biologics if the expulsion pathway proves broad. The finding could shift drug modality selection for multiple oncogenes traditionally pursued with small molecules.
Forward Looking
- Watch for BMS to clarify Opdualag development strategy beyond melanoma after Immutep's LAG-3 lung cancer failure raises questions about the class's viability in solid tumors.
- Salspera's Phase 3 trial design disclosures in coming weeks will reveal whether bacterial oncolytics target cold tumors as monotherapy or pursue checkpoint inhibitor combinations in hot tumors.
- Academic and biotech groups will race to validate the cancer cell protein expulsion mechanism in multiple tumor types and identify which expelled targets offer the best therapeutic index for antibody or CAR-T development.
- Microbiome therapy data from the completed allo-HSCT Phase 2a trial expected in Q2 2026 could catalyze increased pharma investment in microbiome modulation for blood cancers if GVHD reduction is substantial.